Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly's US Bamlanivimab Contract Raises Difficult Allocation Considerations

Oct 28 2020

• By Jessica Merrill

Open red metal empty medicine cabinet hanging on a dark gray marble wall background — Availability of Lilly's antibody for COVID-19 will be limited • Source: Shutterstock

Related Companies

Eli Lilly and Company

Regeneron Pharmaceuticals, Inc.

Gilead Sciences, Inc.

AstraZeneca PLC

Additional Topics

United States Coronavirus COVID-19 Pricing Debate Government Payers Commercial Infectious Diseases BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.